Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1882-1884

  Jacobsen, Mette D ^a   Whyte, Julie A ^a   Odds, Frank C ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 34248329893     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01525-06     Document Type: Article

References (17)

1. Arthington-Skaggs, B. A., W. Lee-Yang, M. A. Ciblak, J. P. Frade, M. E. Brandt, R. A. Hajjeh, L. H. Harrison, A. N. Sofair, and D. W. Warnock for the Candidemia Active Surveillance Group. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481.
2. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.
3. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
4. CLSI. 2006. Quality control minimal inhibitory concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints; informational supplement, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, and J. L. Rodriguez-Tudela. 2005. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin. Microbiol. Infect. 11:486-492.
6. Douglas, C. M., J. A. Dippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
7. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.
8. MacCallum, D. M., H. Findon, C. C. Kenny, G. Butler, K. Haynes, and F. C. Odds. 2006. Different consequences of ACE2 and SWI5 gene disruptions for virulence of pathogenic and nonpathogenic yeasts. Infect. Immun. 74:5244-5248.
9. McCormack, P. L., and C. M. Perry. 2005. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65:2049-2068.
10. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., vol. 17, p. 9. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Odds, F. C., A. J. P. Brown, and N. A. R. Gow. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279.
12. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Cantón, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobemado, R. Handke, M. Laverdière, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Pemán, S. Perea, J. R. Perfect, M. A Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
13. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozanochiu, A. Espinelingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
14. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
15. Stevens, D. A., T. C. White, D. S. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178.
16. Sullivan, D. J., G. P. Moran, and D. C. Coleman. 2005. Candida dubliniensis: ten years on. FEMS Microbiol. Lett. 253:9-17.
17. Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.